Synaptogenix Inc. (SNPX)
NASDAQ: SNPX
· Real-Time Price · USD
3.98
0.40 (11.17%)
At close: Jun 24, 2025, 3:59 PM
4.04
1.51%
After-hours: Jun 24, 2025, 05:50 PM EDT
Company Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development.
It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease.
The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.
The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix Inc.
| Country | United States |
| IPO Date | Dec 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Alan J. Tuchman M.D., MBA(FAAN) |
Contact Details
Address: 1185 Avenue of the Americas New York City, New York United States | |
| Website | https://www.synaptogen.com |
Stock Details
| Ticker Symbol | SNPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001571934 |
| CUSIP Number | 87167T201 |
| ISIN Number | US87167T3005 |
| Employer ID | 46-1585656 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alan J. Tuchman M.D., MBA(FAAN) | Chief Executive Officer & Director |
| Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer & Secretary |
| Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | D | Filing |
| Jun 09, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| Apr 07, 2025 | 4 | Filing |
| Apr 07, 2025 | 4 | Filing |
| Apr 07, 2025 | 4 | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 06, 2024 | 8-K | Current Report |
| Nov 20, 2024 | DEFA14A | Filing |